Neutra Corporation (OTC PINK:NTRR) subsidiary VIVIS will enter new business lines: equipment leasing and CBD production consulting, aimed at generating additional revenue. The company has already opened two CBD production plants in 2020, with the Katy facility recently operational and enhancing product offerings with tinctures and gummies. VIVIS plans to provide consulting for setting up CBD facilities and lease production equipment to interested companies. This strategic move underscores Neutra's commitment to growing within the thriving CBD market.
Neutra Corporation (OTC PINK:NTRR) subsidiary VIVIS has signed a letter of intent with an Oklahoma cannabis firm to expand operations, leveraging VIVIS' expertise and industry contacts. This partnership is expected to generate new revenue streams and facilitate the development of CBD products. The demand for hemp-based CBD products continues to grow, with a report indicating a 40% increase in consumption among users. Improved production and distribution have made premium CBD products more affordable, broadening the customer base for VIVIS.
Neutra Corporation (OTC PINK:NTRR) plans to open a second CBD manufacturing facility in Texas, enhancing operational capacity. Following the successful launch of its Katy plant in April 2020, the company is acquiring additional equipment for its current site. Despite challenges from the COVID-19 pandemic, demand for hemp-based CBD products has surged, with 40% of users increasing their consumption. Neutra's subsidiary, VIVIS, is set to expand its product line with the new facility, leveraging its third-party lab testing for quality assurance, which distinguishes its offerings in the market.
Neutra Corporation (OTC PINK:NTRR) is embarking on a new CBD product development project in collaboration with a significant group in Oklahoma. The project will leverage their state-of-the-art facility in Katy to produce a diverse array of hemp-based CBD products, including tinctures and gummies, which are THC-free and compliant. Despite challenges from COVID-19, demand for these products remains strong, with 40% of CBD users reporting increased consumption. VIVIS's products are uniquely differentiated by third-party lab testing for purity and potency.